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H I G H L I G H T S
• Lp(a) levels above 30–50mg/dL associate with calcific aortic valve stenosis.• he-FH patients have marked lifelong elevation of serum LDL-cholesterol level.• AVC among he-FH patients is more frequent than in the general population.• Lp(a) life years is a useful metric of cumulative burden of Lp(a).• Apo(a) antisense oligonucleotides effectively lower Lp(a) concentration.








A B S T R A C T
A large number of epidemiological studies in ethnically diverse populations show that lipoprotein(a) [Lp(a)]
levels above 30–50mg/dL are significantly associated with calcific aortic valve stenosis, although less so in
African Americans. Patients with heterozygous familial hypercholesterolemia (he-FH) have a marked lifelong
elevation of serum low-density lipoprotein cholesterol (LDL-C) level, and the prevalence of aortic valve calci-
fication (AVC) is at least two-fold higher among adult he-FH patients compared with healthy controls.
Additionally, Lp(a) levels above 50mg/dL were recently found to be an independent risk factor for AVC among
asymptomatic statin-treated he-FH patients. Given that worldwide an estimated 1.4 billion people have an Lp(a)
level over 50mg/dL, and that one out of 250 individuals has he-FH, then globally about 5 million he-FH patients
should have an Lp(a) level higher than 50mg/dL. However, because Lp(a) levels are, on average, significantly
higher in he-FH patients than the general population, the actual number of he-FH patients with such high Lp(a)
levels must be even higher.
We proposed recently that Lp(a) life-years is a useful metric of cumulative burden of risk for atherosclerotic
cardiovascular disease (ASCVD), and now posit that this metric may be extended to the development of AVC. The
Lp(a) life-years illustrates the age-dependent exposure to a given Lp(a) level (years x mg/dL). Effective novel
pharmacotherapies using apo(a) antisense oligonucleotides (ASOs) or small interfering RNA (siRNA)-based
therapies targeting the hepatic expression of apo(a) offer unprecedented potential for significant reduction in the
cumulative exposure of the aortic valves to Lp(a), and need to be tested in controlled clinical trials on the
progression of AVC.
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1. Introduction
This review discusses the current knowledge on lipoprotein(a) [Lp
(a)] as a risk factor of aortic valve calcification (AVC), an important
precursor of clinical aortic stenosis (AS), in heterozygous familial hy-
percholesterolemia (he-FH) patients, and also takes note of some new
treatment options to lower an elevated Lp(a) level. Although the precise
etiology of AVC is still unknown [1,2], a recent study found association
between genetically determined Lp(a) levels and AVC and incident AS,
supporting a causal role for Lp(a) in the development of the clinical
calcific aortic valve disease in the general population [3]. The pre-
valence of aortic valvular abnormalities increases with age. Indeed, a
clear increase in the prevalence of aortic sclerosis, which presents an
early stage of the calcific aortic valve disease, is present in about every
five persons in the group of 65- to 75-year-old people in the general
population [4]. In this age group, the prevalence of clinically significant
AS is about 1–3%. Interestingly, in heterozygous familial hypercholes-
terolemia (he-FH), the figures for AVC, i.e. the stage preceding AS [5],
are significantly higher when compared to controls [6], a finding that
inspired us to review this topic.
The incidence of a congenital bicuspid valve is approximately 1–2%
[7]. Among the affected individuals, the risk of AS is increased com-
pared with those having a tricuspid, i.e., anatomically a normal valve.
Subjects with a bicuspid valve usually develop AS 1 to 2 decades earlier
than those with a tricuspid valve, reflecting the importance of blood
flow abnormalities in the pathogenesis of AS [8]. For severe AS, the
treatment is to replace the aortic valve by open heart surgery, or by
transcatheter aortic valve implantation (TAVI), a procedure which has
revolutionized the treatment of AS, particularly in elderly patients who
are not eligible for major surgery [9].
2. FH genotype and phenotype
Familial hypercholesterolemia (FH) is caused by mutations in the
low-density lipoprotein receptor (LDLR) gene [10], the apolipoprotein-
B gene (apoB) [11] or the proprotein convertase subtilisin/kexin type 9
(PCSK9) gene [12]. The vast majority of the mutations causing FH (so
far over 1.700) are found in the LDLR gene [13], while the minority of
mutations are in the apoB or PCSK9 gene [14]. The prevalence of het-
erozygous FH has been traditionally estimated to be one case out of 500
individuals. Recently, however, it has been found that this figure is too
conservative, the new estimation for the prevalence of heterozygous FH
(he-FH) being one out of 200–250 persons [15–18].
Patients with he-FH have, on average, a life-long two-fold elevation
of serum LDL-cholesterol (LDL-C) level starting already in utero [19]. If
left untreated, the elevated LDL-C leads to early onset of atherosclerotic
changes in the susceptible areas of the arterial tree, particularly in
coronary arteries and the proximal aorta. Indeed, among he-FH pa-
tients, angiographically detectable stenosing coronary atherosclerosis
has been observed already in 25-year old males and 30-year old females
[20], and severe atherothrombotic complications, such as premature
acute myocardial infarction (AMI), may occur in male he-FH patients
already in early adulthood.
3. Calcific aortic valvulopathy in the general populations, in
African Americans, and in he-FH
As indicated above, in the general population, the prevalence of AVC
increases with age [21,22]. In a recent preliminary study involving a small
group of patients attending a large general practice for non-cardiac rea-
sons, moderate or severe AS was observed in 5% of the patients aged>75
years [23]. It is important to remember that the severity of AVC is asso-
ciated with atherosclerotic cardiovascular disease (ASCVD) [24] and that
it independently predicts cardiovascular events [25].
Interestingly, race-related differences in AS exist, with African
Americans having significantly less likely calcification in the aortic
valves than whites. Thus, in a large hospital database study carried out
in the US involving 2.1 million patients, African-American individuals
had less likely severe aortic stenosis due to degenerative calcific disease
(adjusted OR 0.47 [0.36, 0.61]) [26]. In this study, none of the studied
known common risk factors of AS could explain the lower prevalence of
severe AS among the African Americans. Importantly, however, like in
other ethnic groups, the genetic variation of Lp(a) levelsassociates with
AVC and clinical AS also in African Americans [3]. Since in African
Americans the levels of Lp(a) are significantly higher than in Cauca-
sians [27], some protective factors counteracting the AVC- and AS-
promoting effects of Lp(a) seem to be operative.
Regarding the manifestations of hypercholesterolemic aortic val-
vulopathy in FH, both the He-FH and homozygous form of FH (ho-FH),
in which the LDL-C levels are extremely high already in utero, have
received early attention [28]. Thus, Buja and co-workers [29] reported
that the aortic valve of an autopsied 20-week-old fetus with ho-FH
contained numerous lipid-filled cells and fibrous thickening, and that a
9-year-old girl with ho-FH required open-heart surgery for aortic valve
replacement. Thus, this pathologic valvular condition in FH homo-
zygotes appears to represent a greatly accelerated and lipid-dominated,
rather than calcification-dominated, form of aortic valvulopathy. Al-
ready 20 years ago, Rallidis and co-workers showed, among severely
affected he-FH patients a positive correlation between the mean
transaortic gradient, severity of aortic valve root involvement, and the
[cholesterol x years]-score [30]. However, in those early days, the
possible role of Lp(a) remained unnoticed.
Two studies on the prevalence of AVC in he-FH patients were re-
ported recently (Table 1). Kate et al. [6] employed computed tomo-
graphy (CT) and estimated AV calcium scores in 145 DNA-verified and/
or clinically diagnosed asymptomatic he-FH patients treated with sta-
tins. The prevalence of AVC was 41% among he-FH patients with a
mean age of 52 years and 21% among controls with a mean age of 56
years (Table 1). This study showed that AVC is about two-fold more
frequent among he-FH patients compared with controls. Of particular
significance was the comparison between he-FH patients with LDL re-
ceptor-negative mutations and those with receptor-defective mutations,
the former ones having LDL receptors without any residual functioning
capacity to remove LDL particles from the circulation, and the latter
ones having LDL receptors with some residual capacity for LDL re-
moval. As expected, LDL-C levels were higher in the former more se-
verely affected group and lower in the latter group of he-FH patients.
Strikingly, he-FH patients with LDL receptor-negative mutations had a
higher prevalence of AVC (53%) compared with those with LDL re-
ceptor-defective mutations (33%), and the AVC process advanced faster
with age in the LDL receptor-negative patients. In another recent CT
scanning study involving 129 DNA-verified and/or clinically diagnosed
asymptomatic he-FH patients with a median age of 51 years, 61% of the
patients were found to have AVC [31]. This figure is even higher than
that (about 50%) among subjects over 75 years of age in the general
population. Both of the above-cited studies reveal that he-FH patients
are likely to have a large extent of subclinical AVC when compared with
the subjects in the general population.
Table 1
Aortic valve calcification (AVC) in heterozygous familial hypercholesterolemia
(he-FH).
Subject of study Age (years) Number AVC present
Number (%)
Reference







Lp(a) and AVC he-FH 51 (46–59)b
no controls
129 79 (61%) [31]
AVC= aortic valve calcification.
a Mean ± standard deviation.
b Median (interquartile range).
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3.1. Inflammatory cells, apolipoproteins, and calcific aortic valvulopathy
The progress of calcific aortic valvulopathy from early to advanced
stenotic valvular lesions has many similarities with atherosclerosis.
Thus, it is caused by a multitude of inflammatory reactions and pro-
cesses particularly on the aortic side of the valve in which turbulent
flow conditions exist [1,4,32]. In addition, oxidative stress and en-
dothelial dysfunction are essential parts of the pathogenesis of calcific
aortic valvulopathy leading to fibrotic remodelling and calcification of
the aortic valve [5]. The early lesions contain infiltrates of in-
flammatory cells, notably of macrophages, and also of some T cells
[33], and in advanced lesions also mast cells are found [34]. Im-
munohistochemical studies have shown that already the early lesions,
but not the normal regions of the valve leaflets, contain several sub-
classes apolipoproteins (apo's), notably apo(a) reflecting the presence of
Lp(a), and also apoB and apoE, all of these apolipoproteins indicating
the presence of atherogenic and proinflammatory plasma-derived li-
poproteins in the early valvular lesions [32]. In the valves with very
advanced lesions causing severe AS, also apoA-I is present, reflecting
the presence of HDL-particles, which may have, in addition to anti-in-
flammatory effects, also an anti-calcifying effect in human aortic valves
[35]. Taken together, both infiltration of inflammatory cells and ac-
cumulation of lipoprotein-derived lipids participate in the initiation and
progression of AS.
3.2. Lipoprotein(a) and calcific aortic valvulopathy in he-FH
In the general population, increased levels of Lp(a) in serum are
related not only to aortic valve stenosis, but also to aortic valve lesions
before a clinically significant AS develops [32,36–41]. It has also been
shown that genetic alterations in the LPA locus, which are reflected in
the variation of Lp(a) levels, are related to aortic valve calcification and
aortic stenosis [3,42]. The overall data support the hypothesis that
during an extended latent period, continuous plasma exposure of the
aortic valve to Lp(a)-associated molecules in the circulation induces
inflammation and calcification of the valve [41]. Because patients with
he-FH have significantly higher Lp(a) levels than non-FH subjects in the
general population [43], they might be potentially at higher risk of
premature AS. Relevant to the development of AVC is that in the
-mentioned study by Kate et al. [6] on 145 he-FH patients, AVC was
present in 26%, 48%, and 56% in the age categories of 40–50 years,
51–58 years, and 59–70 years, respectively. Thus, an elevated con-
centration of Lp(a) appears to be a critical etiological component in the
pathological process leading to AVC. Further, we can hypothesize that
lowering of Lp(a) concentration is one option to decrease the risk of
AVC, and, ultimately, also AS. However, proof of this concept requires
testing in long-lasting echocardiographic trials with a potent Lp(a)-
lowering agent [44].
The serum concentration of Lp(a) in he-FH was found, for the first
time, to be an independent predictor for AVC in a study in which 129
(aged 40–69 years) he-FH patients were examined by computed to-
mography (CT) [31]. Serum Lp(a) levels were higher in he-FH patients
with AVC 43.4 mg/dL [IQR (interquartile range) 10.6–105.0)] when
compared with those in the he-FH patients without AVC 24.5 mg/dL
(IQR 5.5–49.1). AVC was associated with serum Lp(a) concentration,
age, body mass index, blood pressure, duration of statin use, cholesterol
year score, and coronary artery calcification score. Based on the above
finding, the authors concluded that it is possible that an elevated serum
Lp(a) concentration may in later life accelerate the development of AS
[31]. Considering that aging significantly increases the level of plasma
Lp(a) [45], such age-related elevation of Lp(a) may also act as a me-
chanism for AS in the elderly.
3.3. Lp(a) and oxidized phospholipids
It is widely accepted that the Lp(a)-associated risk for ASCVD is
largely caused by the oxidized phospholipids (OxPLs) contained in the
Lp(a) particles, particularly when present in the most atherogenic Lp(a)
particles that are associated with both high plasma Lp(a) levels and
small apo(a) isoforms [46]. In a recent Doppler echocardiography study
of 269 patients, aged 18–82 years, who had mild-to-moderate aortic
stenosis (AS) at baseline (the Aortic Stenosis Progression Observation:
Measuring Effects of Rosuvastatin or ASTRONOMER study), Lp(a) and
OxPL-apoB levels were the two factors independently explaining the
progression rate of AS [38]. Importantly, the OxPLs located on apoB-
100 (OxPL-apoB) of the Lp(a) particle mainly reflect the proin-
flammatory component of the proatherogenic activity of Lp(a).
The molecular mechanisms explaining how serum Lp(a) leads to
development of AVC remain to be explored. Like in atherosclerosis, the
mechanism might be related to the fact that Lp(a) has a high affinity for
OxPLs and that it may deliver OxPLs to the valvular tissue [38,47]. It is
possible that autotaxin (ATX), which is present and overexpressed in a
mineralized aortic valve, hydrolyzes OxPL into lysophosphatidic acid
(LPA) [48], a molecule that triggers fibrosis [49]. Both OxPL and LPA
are proinflammatory and can induce calcification [50]. Based on this
hypothesis, the potential target molecules to prevent AVC are listed in
Table 2. Additionally, fibrinogen accumulation in the aortic valves has
been shown to contribute to the pathogenesis of AS, and partially de-
graded fibrin has an affinity for Lp(a) [51,52].
4. Guidelines and lipoprotein(a)
The finding that Lp(a) is an independent risk factor for AS is
strongly supported by several genetic studies with patients having ge-
netically elevated levels of Lp(a) [37,40,53–56]. However, it has taken
a long time to establish guidelines regarding the measurement of Lp(a)
in specific populations like the he-FH [57], however a consensus ap-
pears now to have been reached, although the Lp(a) concentration cut-
off level above which active treatment is required is still under debate
[58]. The European Society of Cardiology/European Atherosclerosis
Society Guidelines for the Management of Dyslipidemias recommend
measurement of Lp(a) concentration in all patients with he-FH [59].
Regarding the general population, this recommendation considers the
ASCVD risk to be significant when serum Lp(a) concentration is >
50mg/dL, while The Canadian Cardiovascular Society Guidelines re-
commend the risk threshold to be 30mg/dL [60]. It can be argued that,
in contrast to the general population, a more stringent treatment goal
for Lp(a) is needed in he-FH, i.e., a risk threshold and treatment goal
under 30mg/dL appears justified [61]. Actually, since all adult he-FH
patients are high-risk patients, the elderly he-FH patients often being
even very-high-risk patients, it appears that lowering the serum Lp (a)
concentration as much as possible would be appropriate by analogy to
the very demanding strategy of lowering LDL-C concentration in these
particular patients.
The recent recommendation by the National Heart, Lung, and Blood
Institute (NHLBI) working group estimated that the global number of
people with an Lp (a) concentration over 50mg/dL is about 1.4 billion
[44]. If we estimate that about every 250th individual has he-FH, then
approximately 5 million he-FH patients having an Lp(a) level over
50mg/dL should exist worldwide. Because patients with he-FH have
significantly higher Lp(a) levels than the non-FH subjects in the general
Table 2
Main potential therapeutic targets to prevent aortic valve calcification.
Potential target moleculea Proposed pathogenic mechanism of action
Lipoprotein(a) Carries cholesterol, apoB, apo(a), and Ox (PLs)
Oxidized phospholipids (OxPLs) Induce oxidative stress and are proinflammatory
Autotaxin Generates LPA from OxPLs
Lysophospatidic acid (LPA) Induces fibrosis and calcification
a Modified from Ref. [41].
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population [43], the number of he-FH patients with such high Lp(a)
levels must be even greater.
5. Lipoprotein(a) life-years as an exemplar of CV risk in he-FH
We recently proposed the possibility of using “Lp(a) life-years” as
another metric of cumulative burden of ASCVD risk in patients with he-
FH [61]. Since Lp(a) appears to be a pathogenic component of AVC, this
metric can be extended to include this disease, as well. Lp(a) life-years
illustrates the age-dependent exposure to Lp(a) of a given concentration
(years x mg/dL). The analogy for using Lp(a) life-years in he-FH is
based on the use of LDL-C life-years to illustrate the lifelong burden of a
more or less stable genetically increased level of LDL-C (years x mg/dL
or mmol/L) in he-FH [62]. Like the plasma levels of increased LDL-C in
he-FH, those of Lp(a) are not constant, as they increase with age, and
may also fluctuate, especially in patients with liver and kidney disease
[63]. Thus, a single Lp(a) value may be misleading when extrapolated
to calculate Lp(a) life-years. Accordingly, the plasma level of Lp(a)
should be measured several times, and the mean value then used to
make a more reliable estimation of an actual life-long situation. If an
elevated Lp(a) is pharmacologically lowered, as it is currently possible,
it is advisable to measure the Lp(a) level on an annual basis.
Fig. 1A illustrates cumulative Lp(a) life-years up to the age of 80
years of a person having an Lp(a) level of either 30mg/dL or 50mg/dL,
i.e. levels which correspond to the cut-off levels based on the re-
commendation of the Canadian Cardiovascular Society Guidelines [60]
and The European Society of Cardiology/European Atherosclerosis
Society [59], respectively. The figure depicts that a person having an Lp
(a) level of 30mg/dL will reach an Lp(a) life-years value of 2400 (years
x mg/dL), while a person having an Lp(a) level of 50mg/dL will reach
an Lp(a) life-years value which is much higher, i.e., 4000 (years x mg/
dL), when he/she reaches the age of 80 years.
Fig. 1B shows the cumulative Lp(a) life-years when an individual
has a very high (100mg/dL) Lp(a) serum concentration. Based on the
Canadian recommendation, this individual reaches the recommended
maximum Lp(a) life-years already at the age of about 25 years. Ac-
cording to a recent CT study among he-FH patients, an Lp(a) level of
30mg/dL or less was not a risk for AVC, but Lp(a) levels over 50mg/dL
posed a significant risk for AVC [31]. Regarding the above-mentioned
high-risk individual, an early Lp(a) lowering therapy would be very
appropriate, since if such treatment is started in late adulthood, the
cumulative Lp(a) burden has already reached an excessive level. In
summary, by analogy with rescue therapy of an untreated middle-aged
he-FH patient with high cumulative burden of LDL-C [64], an adult he-
FH patient with a high Lp(a) serum concentration (in addition to the
high LDL-C level) needs very effective rescue therapy to lower the cu-
mulative burden of Lp(a).
6. Challenges related to Lp(a) lowering therapies
In a very recent meta-analysis including 29,069 patients, who had
participated in randomised placebo-controlled statin trials, those with
an elevated Lp(a) level of 30mg/dL or higher at baseline and those with
elevated Lp(a) level of 50mg/dL or higher while on statin treatment,
showed an independent linear relation with risk of CV events [65].
These data show that a residual risk remains in patients with an ele-
vated Lp(a) (mainly > 50mg/dL) even while taking statins, and
clearly calls for additional trials to test for specific therapies to lower Lp
(a).
Several issues need to be taken into account before implementing
effective rescue therapies in the routine clinical care of he-FH patients.
The most important clinical challenges are listed in Table 3. The very
recent data of the Odyssey Outcomes Trial regarding the effects of the
PCSK9 inhibitor alirocumab on serum Lp(a) concentration and on car-
diovascular outcomes are interesting [66]. In this outcome trial on
patients with recent major adverse cardiac event (MACE), it was found
that Lp(a) lowering by alirocumad is associated with a reduction of
MACEs, and that reduction is independent of baseline LDL-C level and
concurrent LDL-C lowering. The considerable Lp(a)-lowering effect of
PCSK9-mAbs seems not to be related to the mAb type, either alir-
ocumab or evolocumab, as in a recent meta-analysis including twenty-
seven randomised clinical trials with 11,864 participants PCSK9-mAbs
were found to significantly reduce Lp(a) (−21.9%; 95% CI -24.3 to
−19.5) [67]. It remains to be seen whether the PCSK9-mAbs will re-
duce not only MACEs but also the development of AS.
7. Conclusions
All he-FH patients have a lifelong two- to three-fold elevation of
LDL-C levels, and a large proportion of them also have a lifelong ele-
vation of Lp(a) level. The combination of an elevated LDL-C and an
elevated Lp(a) level in he-FH patients not only increases the risk of
ASCVD, but also potentially also the risk of calcific aortic valvulopathy.
The concept of Lp(a) life-years emphasizes the lifelong burden of ele-
vated serum Lp(a) level and the need to lower serum Lp(a) con-
centration effectively in he-FH, since in such patients the circulating
Fig. 1. Cumulative Lp(a) burden.
(A) Cumulative Lp(a) burden (years x mg/dL) up to
the age of 80 years of a person having an Lp(a) level
of either 30mg/dL or 50mg/dL, i.e., the cut-off level
above which active treatment is required is based on
the recommendation of the Canadian Cardiovascular
Society (CCS) Guidelines [60] and The European
Society of Cardiology (ESC)/European Athero-
sclerosis Society (EAS) [59], respectively. (B) Cu-
mulative Lp(a) burden in two he-FH patients, one
having a very high (100mg/dL) and another having
a relatively low (30mg/dL) Lp(a) serum concentra-
tion. The Lp(a) concentrations are based on the mean
of two separate measurements. The he-FH patient
with the high Lp(a) concentration reaches the cu-
mulative Lp(a) burden of the 80-year old heFH pa-
tient with the relatively low Lp(a) level already at the
age of about 25 years. According to a recent com-
puted tomography study in he-FH patients, Lp(a) le-
vels over 50mg/dL pose a significant risk for AVC,
but levels of 30mg/dL or less do not [31]. Regarding
the above presented high-risk he-FH patient, Lp(a)
lowering therapy would be very appropriate.
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levels of two artery-damaging lipoprotein particles, i.e. LDL particles
and Lp(a) particles, are elevated since birth. Especially, the new apo(a)
antisense oligonucleotides which lower serum Lp(a) concentration by
about 70–90% are very promising to meet this challenge. These new
apo(a) antisense oligonucleotides, and also the specific siRNAs under
development, all need to be tested in controlled clinical intervention
trials to learn about their effects on the progression of ASCVD [68–73].
In he-FH patients, this promising mode of selective Lp(a)-lowering
therapy has the prospects of having a double target: both the athero-
sclerosis-susceptible areas of the arterial wall and the aortic valves.
Such therapy would be probably most efficient among those he-FH
patients who have a strongly elevated Lp(a) level and early signs of
calcific aortic valvulopathy.
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